Phase 3 Study Evaluating the Safety and Effectiveness of Investigational Drug Mezigdomide in Combination with Carfilzomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma SUCCESSOR-2

What's the purpose of this trial?

The goal of this clinical trial is to learn more about the safety and effectiveness of investigational drug Mezigdomide when combined with approved treatments carfilzomib and dexamethasone compared to approved treatments carfilzomib and dexamethasone alone in participants with relapsed and refractory multiple myeloma. 

This trial is currently open and accepting patients.

What will happen during the trial?

This study is being conducted in two different parts, or stages.

In Stage 1, there are four planned groups, also called arms. Three of the four arms will receive different dose levels of investigational drug mezigdomide in combination with approved treatments carfilzomib and dexamethasone, and one arm will receive approved treatments carfilzomib and dexamethasone. 

In Stage 2, there are two planned arms. One arm will receive mezigdomide (at the selected dose determined by stage 1), Carfilzomib and Dexamethasone, and the other arm will receive Carfilzomib and Dexamethasone.  

You may be able to join this trial if you:

The following criteria is a partial list of reasons why patients may be eligible to participate in this clinical trial. Further evaluation with a medical professional is required.

  • have measurable disease according to the trial criteria.
  • have received at least one prior line of therapy, including lenalidomide and an anti-CD38 monoclonal antibody (for instance, daratumumab or isatuximab)
  • have not previously received investigational drug mezigdomide or Carfilzomib.
  • have not previously received an allogeneic stem cell transplant, and have not had an autologous stem cell transplant in the three months before joining the study.
  • have adequate bone marrow and kidney function as described in the trial criteria.

Additional eligibility criteria apply and can be explained by the study doctor. 

Additional Trial Information

Phase 3

Enrollment: 525 patients (estimated)

View More

Trial Locations

All Trial Locations

View all clinical trial locations sorted by state.


Mitchell Cancer Institute University of South Alabama

Mobile, AL

Open and Accepting


Kaiser Permanente Orange County Irvine Medical Center

Irvine, CA

Open and Accepting

Los Angeles Cancer Network (Los Angeles)

Los Angeles, CA

Not Yet Accepting

Los Angeles Cancer Network (Van Nuys)

Los Angeles, CA

Not Yet Accepting

Los Angeles Cancer Network (Pasadena)

Pasadena, CA

Not Yet Accepting


Winship Cancer Institute Emory University

Atlanta, GA

Not Yet Accepting

Augusta University Medical Center

Augusta, GA

Not Yet Accepting


Saint Alphonsus Cancer Care Center (Boise)

Boise City, ID

Not Yet Accepting


Our Lady of the Lake Medical Oncology, LLC

Baton Rouge, LA

Not Yet Accepting


Dana-Farber Cancer Institute (Main)

Boston, MA

Not Yet Accepting

New Jersey

Regional Cancer Care Associates - Little Silver

Little Silver, NJ

Not Yet Accepting

New York

Montefiore Medical Center

Bronx, NY

Open and Accepting


OhioHealth Riverside Methodist Hospital

Columbus, OH

Open and Accepting

South Carolina

Charleston Hematology Oncology Associates PA West Ashley

Charleston, SC

Not Yet Accepting


Houston Methodist Hospital

Houston, TX

Open and Accepting

Baylor Scott & White Hospital

Temple, TX

Open and Accepting


Northwest Medical Specialties (Gig Harbor)

Gig Harbor, WA

Open and Accepting

West Virginia

WVU Cancer Institute

Morgantown, WV

Not Yet Accepting
Interested in this trial?
  • Call us today 😀 keyboard_arrow_right

    We know how difficult and confusing this process can be. If you are interested in this clinical trial or have questions, you can call us at any time. You can also send us a direct message with questions.

    (888) 828-2206
  • If you are interested in keeping an eye on this trial, you can add it to your list of favorite trials. We'll send you alerts when this trial is updated.

  • Talk to your doctor keyboard_arrow_right

    You can print an overview of this trial to take in to your next appointment. Your doctor can help you understand if this trial may be right for you.

Still need help? Send us a message

SparkCures Verified

Learn more about how we work with trial sponsors